Table of Pharmacogenomic Biomarkers in Drug Labeling
Pharmacogenomics can play an important role in identifying responders and non-responders to medications, avoiding adverse events, and optimizing drug dose. Drug labeling may contain information on genomic biomarkers and can describe:
- Drug exposure and clinical response variability
- Risk for adverse events
- Genotype-specific dosing
- Mechanisms of drug action
- Polymorphic drug target and disposition genes
The table below lists FDA-approved drugs with pharmacogenomic information in their labeling. The labeling for some, but not all, of the products includes specific actions to be taken based on the biomarker information. Biomarkers in the table include are not limited to germline or somatic gene variants, functional deficiencies, expression changes, and chromosomal abnormalities.
This table does not include non-human genetic biomarkers (e.g., viral or bacterial) i.e., microbial variants that influence sensitivity to anti-invectives; biomarkers that are used solely for diagnostic purposes unless they are linked to drug activity or used to identify a specific subset in whom prescribing information differs (e.g., for genetic diseases). Therapeutic areas do not necessarily reflect the FDA review division.
Pharmacogenomic information can appear in different sections of the labeling. Relevant sections of the labeling with such information are noted in the last column of the table. For more information on the relevance of information in various parts of drug labeling (e.g. Indications and Usage, Dosage and Administration, Boxed Warning, etc.), please refer to the appropriate labeling guidance. For information on the FDA's initiative to improve prescription drug labeling, visit the FDA/CDER Learn website.
-
Pharmacogenomic Biomarkers in Drug Labeling
Drug | Therapeutic Area | HUGO Symbol | Referenced Subgroup | Labeling Sections |
---|---|---|---|---|
Abacavir | Infectious Diseases | HLA-B | HLA-B*5701 allele carriers | Boxed Warning, Contraindications, Warnings and Precautions, Patient Counseling Information |
Ado-Trastuzumab Emtansine | Oncology | ERBB2 | HER2 protein overexpression or gene amplification positive | Indications and Usage, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
Afatinib | Oncology | EGFR | EGFR exon 19 deletion or exon 21 substitution (L858R) mutation positive | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology, Clinical Studies, Patient Counseling Information |
Amitriptyline | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Precautions |
Anastrozole | Oncology | ESR1, PGR | Hormone receptor positive | Indications and Usage, Clinical Pharmacology, Clinical Studies |
Aripiprazole | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Clinical Pharmacology, Dosage and Administration |
Arsenic Trioxide | Oncology | PML/RARA | PML/RARα (t(15;17)) gene expression positive | Boxed Warning, Clinical Pharmacology, Indications and Usage, Warnings |
Atomoxetine | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Dosage and Administration, Warnings and Precautions, Drug Interactions, Clinical Pharmacology |
Atorvastatin | Endocrinology | LDLR | Homozygous familial hypercholesterolemia | Indications and Usage, Dosage and Administration, Warnings and Precautions, Clinical Pharmacology, Clinical Studies |
Azathioprine | Rheumatology | TPMT | TPMT intermediate or poor metabolizers | Dosage and Administration, Warnings and Precautions, Drug Interactions, Adverse Reactions, Clinical Pharmacology |
Boceprevir | Infectious Diseases | IFNL3 | IL28B rs12979860 T allele carriers | Clinical Pharmacology |
Bosutinib | Oncology | BCR/ABL1 | Philadelphia chromosome (t(9;22)) positive | Indications and Usage, Adverse Reactions, Clinical Studies |
Brentuximab Vedotin | Oncology | TNFRSF8 | CD30 positive | Indications and Usage, Description, Clinical Pharmacology |
Busulfan | Oncology | Ph Chromosome | Ph Chromosome negative | Clinical Studies |
Capecitabine | Oncology | DPYD | DPD deficient | Contraindications, Warnings and Precautions, Patient Information |
Carbamazepine (1) | Neurology | HLA-B | HLA-B*1502 allele carriers | Boxed Warning, Warnings and Precautions |
Carbamazepine (2) | Neurology | HLA-A | HLA-A*3101 allele carriers | Boxed Warning, Warnings and Precautions |
Carglumic Acid | Metabolic Disorders | NAGS | N-acetylglutamate synthase deficient | Indications and Usage, Warnings and Precautions, Special Populations, Clinical Pharmacology, Clinical Studies |
Carisoprodol | Rheumatology | CYP2C19 | CYP2C19 poor metabolizers | Clinical Pharmacology, Special Populations |
Carvedilol | Cardiology | CYP2D6 | CYP2D6 poor metabolizers | Drug Interactions, Clinical Pharmacology |
Celecoxib | Rheumatology | CYP2C9 | CYP2C9 poor metabolizers | Dosage and Administration, Drug Interactions, Use in Specific Populations, Clinical Pharmacology |
Cetuximab (1) | Oncology | EGFR | EGFR protein expression positive | Indications and Usage, Warnings and Precautions, Description, Clinical Pharmacology, Clinical Studies |
Cetuximab (2) | Oncology | KRAS | KRAS codon 12 and 13 mutation negative | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
Cevimeline | Dental | CYP2D6 | CYP2D6 poor metabolizers | Drug Interactions |
Chloroquine | Infectious Diseases | G6PD | G6PD deficient | Precautions |
Chlorpropamide | Endocrinology | G6PD | G6PD deficient | Precautions |
Cisplatin | Oncology | TPMT | TPMT intermediate or poor metabolizers | Clinical Pharmacology, Warnings, Precautions |
Citalopram (1) | Psychiatry | CYP2C19 | CYP2C19 poor metabolizers | Drug Interactions, Warnings |
Citalopram (2) | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Drug Interactions |
Clobazam | Neurology | CYP2C19 | CYP2C19 poor metabolizers | Clinical Pharmacology, Dosage and Administration, Use in Specific Populations |
Clomipramine | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Drug Interactions |
Clopidogrel | Cardiology | CYP2C19 | CYP2C19 intermediate or poor metabolizers | Boxed Warning, Dosage and Administration, Warnings and Precautions, Drug Interactions, Clinical Pharmacology |
Clozapine | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Drug Interactions, Clinical Pharmacology |
Codeine | Anesthesiology | CYP2D6 | CYP2D6 ultra-rapid metabolizers | Boxed Warnings, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology , Patient Counseling Information |
Crizotinib | Oncology | ALK | ALK gene rearrangement positive | Indications and Usage, Dosage and Administration, Drug Interactions, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
Dabrafenib (1) | Oncology | BRAF | BRAF V600E mutation positive | Indications and Usage, Dosage and Administration, Warnings and Precautions, Clinical Pharmacology, Clinical Studies, Patient Counseling Information |
Dabrafenib (2) | Oncology | G6PD | G6PD deficient | Warnings and Precautions, Adverse Reactions, Patient Counseling Information |
Dapsone (1) | Dermatology | G6PD | G6PD deficient | Indications and Usage, Precautions, Adverse Reactions, Patient Counseling Information |
Dapsone (2) | Infectious Diseases | G6PD | G6PD deficient | Precautions, Adverse Reactions, Overdosage |
Dasatinib | Oncology | BCR/ABL1 | Philadelphia chromosome (t(9;22)) positive; T315I mutation-positive | Indications and Usage, Clinical Studies, Patient Counseling Information |
Denileukin Diftitox | Oncology | IL2RA | CD25 antigen positive | Indications and Usage, Warnings and Precautions, Clinical Studies |
Desipramine | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Drug Interactions |
Dexlansoprazole (1) | Gastroenterology | CYP2C19 | CYP2C19 poor metabolizers | Clinical Pharmacology, Drug Interactions |
Dexlansoprazole (2) | Gastroenterology | CYP1A2 | CYP1A2 genotypes | Clinical Pharmacology |
Dextromethorphan and Quinidine | Neurology | CYP2D6 | CYP2D6 poor metabolizers | Clinical Pharmacology, Warnings and Precautions, Drug Interactions |
Diazepam | Psychiatry | CYP2C19 | CYP2C19 poor metabolizers | Drug Interactions, Clinical Pharmacology |
Doxepin | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Precautions |
Drospirenone and Ethinyl Estradiol | Neurology | CYP2C19 | CYP2C19 poor metabolizers | Clinical Pharmacology, Warnings and Precautions, Drug Interactions |
Eltrombopag (1) | Hematology | F5 | Factor V Leiden carriers | Warnings and Precautions |
Eltrombopag (2) | Hematology | SERPINC1 | Antithrombin III deficient | Warnings and Precautions |
Erlotinib (1) | Oncology | EGFR | EGFR protein expression positive | Clinical Pharmacology |
Erlotinib (2) | Oncology | EGFR | EGFR exon 19 deletion or exon 21 substitution (L858R) positive | Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies |
Esomeprazole | Gastroenterology | CYP2C19 | CYP2C19 poor metabolizers | Drug Interactions, Clinical Pharmacology |
Everolimus (1) | Oncology | ERBB2 | HER2 protein overexpression negative | Indications and Usage, Boxed Warning, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
Everolimus (2) | Oncology | ESR1 | Estrogen receptor positive | Clinical Pharmacology, Clinical Studies |
Exemestane | Oncology | ESR1 | Estrogen receptor positive | Indications and Usage, Dosage and Administration, Clinical Studies, Clinical Pharmacology |
Fluorouracil (1) | Dermatology | DPYD | DPD deficient | Contraindications, Warnings, Patient Information |
Fluorouracil (2) | Oncology | DPYD | DPD deficient | Warnings |
Fluoxetine | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Warnings, Precautions, Clinical Pharmacology |
Flurbiprofen | Rheumatology | CYP2C9 | CYP2C9 poor metabolizers | Clinical Pharmacology, Special Populations |
Fluvoxamine | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Drug Interactions |
Fulvestrant | Oncology | ESR1 | Estrogen receptor positive | Indications and Usage, Clinical Pharmacology, Clinical Studies, Patient Counseling Information |
Galantamine | Neurology | CYP2D6 | CYP2D6 poor metabolizers | Special Populations |
Glimepiride | Endocrinology | G6PD | G6PD deficient | Warning and Precautions |
Glipizide | Endocrinology | G6PD | G6PD deficient | Precautions |
Glyburide | Endocrinology | G6PD | G6PD deficient | Precautions |
Ibritumomab Tiuxetan | Oncology | MS4A1 | CD20 positive | Indications and Usage, Clinical Pharmacology, Description |
Iloperidone | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Clinical Pharmacology, Dosage and Administration, Drug Interactions, Specific Populations, Warnings and Precautions |
Imatinib (1) | Oncology | KIT | c-KIT D816V mutation negative | Indications and Usage, Dosage and Administration Clinical Pharmacology, Clinical Studies |
Imatinib (2) | Oncology | BCR/ABL1 | Philadelphia chromosome (t(9;22)) positive | Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies |
Imatinib (3) | Oncology | PDGFRB | PDGFR gene rearrangement positive | Indications and Usage, Dosage and Administration, Clincal Studies |
Imatinib (4) | Oncology | FIP1L1/PDGFRA | FIP1L1/PDGFRα fusion kinase (or CHIC2 deletion) positive | Indications and Usage, Dosage and Administration, Clinical Studies |
Imipramine | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Drug Interactions |
Indacaterol | Pulmonary | UGT1A1 | UGT1A1*28 allele homozygotes | Clinical Pharmacology |
Irinotecan | Oncology | UGT1A1 | UGT1A1*28 allele carriers | Dosage and Administration, Warnings, Clinical Pharmacology |
Isosorbide and Hydralazine | Cardiology | NAT1-2 | Slow acetylators | Clinical Pharmacology |
Ivacaftor | Pulmonary | CFTR | CFTR G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R mutation carriers | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
Lansoprazole | Gastroenterology | CYP2C19 | CYP2C19 poor metabolizers | Drug Interactions, Clinical Pharmacology |
Lapatinib | Oncology | ERBB2 | HER2 protein overexpression positive | Indications and Usage, Clinical Pharmacology, Patient Counseling Information |
Lenalidomide | Hematology | del (5q) | Chromosome 5q deletion | Boxed Warning, Indications and Usage, Clinical Studies, Patient Counseling |
Letrozole | Oncology | ESR1, PGR | Hormone receptor positive | Indications and Usage, Adverse Reactions, Clinical Studies, Clinical Pharmacology |
Lomitapide | Endocrinology | LDLR | Homozygous familial hypercholesterolemia | Indication and Usage, Adverse Reactions, Clinical Studies |
Mafenide | Infectious Diseases | G6PD | G6PD deficient | Warnings, Adverse Reactions |
Maraviroc | Infectious Diseases | CCR5 | CCR5 positive | Indications and Usage, Warnings and Precautions, Clinical Pharmacology, Clinical Studies, Patient Counseling Information |
Mercaptopurine | Oncology | TPMT | TPMT intermediate or poor metabolizers | Dosage and Administration, Precautions, Adverse Reactions, Clinical Pharmacology |
Methylene Blue | Hematology | G6PD | G6PD deficient | Precautions |
Metoclopramide | Gastroentrology | CYB5R1-4 | NADH cytochrome b5 reductase deficient | Precautions |
Metoprolol | Cardiology | CYP2D6 | CYP2D6 poor metabolizers | Precautions, Clinical Pharmacology |
Mipomersen | Endocrinology | LDLR | Homozygous familial hypercholesterolemia | Indication and Usage, Clinical Studies, Use in Specific Populations |
Modafinil | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Drug Interactions |
Mycophenolic Acid | Transplantation | HPRT1 | HGPRT deficient | Precautions |
Nalidixic Acid | Infectious Diseases | G6PD | G6PD deficient | Precautions, Adverse Reactions |
Nefazodone | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Drug Interactions |
Nilotinib (1) | Oncology | BCR/ABL1 | Philadelphia chromosome (t(9 :22)) positive | Indications and Usage, Patient Counseling Information |
Nilotinib (2) | Oncology | UGT1A1 | UGT1A1*28 allele homozygotes | Warnings and Precautions, Clinical Pharmacology |
Nitrofurantoin | Infectious Diseases | G6PD | G6PD deficient | Warnings, Adverse Reactions |
Nortriptyline | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Drug Interactions |
Obinutuzumab | Oncology | MS4A1 | CD20 positive | Indication and Usage, Warnings and Precautions, Description, Clinical Pharmacology, Clinical Studies |
Ofatumumab | Oncology | MS4A1 | CD20 positive | Indications and Usage, Clinical Pharmacology |
Omacetaxine | Oncology | BCR/ABL1 | BCR-ABL T315I | Clinical Pharmacology |
Omeprazole | Gastroenterology | CYP2C19 | CYP2C19 poor metabolizers | Dosage and Administration, Warnings and Precautions, Drug Interactions |
Panitumumab (1) | Oncology | EGFR | EGFR protein expression positive | Indications and Usage, Warnings and Precautions, Clinical Pharmacology, Clinical Studies |
Panitumumab (2) | Oncology | KRAS | KRAS codon 12 and 13 mutation negative | Indications and Usage, Clinical Pharmacology, Clinical Studies |
Pantoprazole | Gastroenterology | CYP2C19 | CYP2C19 poor metabolizers | Clinical Pharmacology, Drug Interactions, Special Populations |
Paroxetine | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Clinical Pharmacology, Drug Interactions |
Pazopanib | Oncology | UGT1A1 | (TA)7/(TA)7 genotype (UGT1A1*28/*28) | Clinical Pharmacology, Warnings and Precautions |
PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate, and Ascorbic Acid | Gastroenterology | G6PD | G6PD deficient | Warnings and Precautions |
Peginterferon alfa-2b | Infectious Diseases | IFNL3 | IL28B rs12979860 T allele carriers | Clinical Pharmacology |
Pegloticase | Rheumatology | G6PD | G6PD deficient | Contraindications, Patient Counseling Information |
Perphenazine | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Clinical Pharmacology, Drug Interactions |
Pertuzumab | Oncology | ERBB2 | HER2 protein overexpression positive | Indications and Usage, Warnings and Precautions, Adverse Reactions, Clinical Studies, Clinical Pharmacology |
Phenytoin | Neurology | HLA-B | HLA-B*1502 allele carriers | Warnings |
Pimozide | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Warnings, Precautions, Contraindications, Dosage and Administration |
Ponatinib | Oncology | BCR –ABL T315I | BCR –ABL T315I mutation | Indications and Usage, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
Prasugrel | Cardiology | CYP2C19 | CYP2C19 poor metabolizers | Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
Pravastatin | Endocrinology | LDLR | Homozygous familial hypercholesterolemia | Clinical Studies, Use in Specific Populations |
Primaquine | Infectious Diseases | G6PD | G6PD deficient | Warnings and Precautions, Adverse Reactions |
Propafenone | Cardiology | CYP2D6 | CYP2D6 poor metabolizers | Clinical Pharmacology |
Propranolol | Cardiology | CYP2D6 | CYP2D6 poor metabolizers | Precautions, Drug Interactions, Clinical Pharmacology |
Protriptyline | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Precautions |
Quinidine | Cardiology | CYP2D6 | CYP2D6 poor metabolizers | Precautions |
Quinine Sulfate | Infectious Diseases | G6PD | G6PD deficient | Contraindications, Patient Counseling Information |
Rabeprazole | Gastroenterology | CYP2C19 | CYP2C19 poor metabolizers | Drug Interactions, Clinical Pharmacology |
Rasburicase | Oncology | G6PD | G6PD deficient | Boxed Warning, Contraindications |
Rifampin, Isoniazid, and Pyrazinamide | Infectious Diseases | NAT1-2 | Slow inactivators | Adverse Reactions, Clinical Pharmacology |
Risperidone | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Drug Interactions, Clinical Pharmacology |
Rituximab | Oncology | MS4A1 | CD20 positive | Indication and Usage, Clinical Pharmacology, Description, Precautions |
Rosuvastatin | Endocrinology | LDLR | Homozygous familial hypercholesterolemia | Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies |
Simeprevir | Infectious Diseases | IFNL3 | IL28B rs12979860 T allele carriers | Clinical studies, Clinical Pharmacology |
Sodium Nitrite | Antidotal Therapy | G6PD | G6PD deficient | Warnings and Precautions |
Sofosbuvir | Infectious Diseases | IFNL3 | IL28B rs12979860 T allele carriers | Clinical Pharmacology, Clinical Studies |
Succimer | Hematology | G6PD | G6PD deficient | Clinical Pharmacology |
Sulfamethoxazole and Trimethoprim | Infectious Diseases | G6PD | G6PD deficient | Precautions |
Tamoxifen (1) | Oncology | ESR1, PGR | Hormone receptor positive | Indications and Usage, Precautions, Medication Guide |
Tamoxifen (2) | Oncology | F5 | Factor V Leiden carriers | Warnings |
Tamoxifen (3) | Oncology | F2 | Prothrombin mutation G20210A positive | Warnings |
Telaprevir | Infectious Diseases | IFNL3 | IL28B rs12979860 T allele carriers | Clinical Pharmacology |
Terbinafine | Infectious Diseases | CYP2D6 | CYP2D6 poor metabolizers | Drug Interactions |
Tetrabenazine | Neurology | CYP2D6 | CYP2D6 poor metabolizers | Dosage and Administration, Warnings, Clinical Pharmacology |
Thioguanine | Oncology | TPMT | TPMT poor metabolizers | Dosage and Administration, Precautions, Warnings |
Thioridazine | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Precautions, Warnings, Contraindications |
Ticagrelor | Cardiology | CYP2C19 | CYP2C19 poor metabolizers | Clinical Studies |
Tolterodine | Genitourinary | CYP2D6 | CYP2D6 poor metabolizers | Warnings and Precautions, Drug Interactions, Use in Specific Populations, Clinical Pharmacology |
Tositumomab | Oncology | MS4A1 | CD20 antigen positive | Indications and Usage, Clinical Pharmacology |
Tramadol | Analgesic | CYP2D6 | CYP2D6 poor metabolizers | Clinical Pharmacology |
Trametinib | Oncology | BRAF | BRAF V600E/K mutation positive | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology, Clinical Studies, Patient Counseling Information |
Trastuzumab | Oncology | ERBB2 | HER2 protein overexpression positive | Indications and Usage, Warnings and Precautions, Clinical Pharmacology, Clinical Studies |
Tretinoin | Oncology | PML/RARA | PML/RARα (t(15;17)) gene expression positive | Clinical Studies, Indications and Usage, Warnings |
Trimipramine | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Drug Interactions |
Valproic Acid (1) | Neurology | POLG | POLG mutation positive | Boxed Warning, Contraindications, Warnings and Precautions |
Valproic Acid (2) | Neurology | NAGS, CPS1, ASS1, OTC, ASL, ABL2 | Urea cycle enzyme deficient | Contraindications, Warnings and Precautions, Adverse Reactions, Medication Guide |
Vemurafenib | Oncology | BRAF | BRAF V600E mutation positive | Indications and Usage, Warning and Precautions, Clinical Pharmacology, Clinical Studies, Patient Counseling Information |
Venlafaxine | Psychiatry | CYP2D6 | CYP2D6 poor metabolizers | Drug Interactions |
Voriconazole | Infectious Diseases | CYP2C19 | CYP219 intermediate or poor metabolizers | Clinical Pharmacology, Drug Interactions |
Vortioxetine | Neurology | CYP2D6 | CYP2D6 poor metabolizers | Dosage and Administration, Drug interactions, Clinical Pharmacology |
Warfarin (1) | Cardiology or Hematology | CYP2C9 | CYP2C9 intermediate or poor metabolizers | Dosage and Administration, Drug Interactions, Clinical Pharmacology |
Warfarin (2) | Cardiology or Hematology | VKORC1 | VKORC1 rs9923231 A allele carriers | Dosage and Administration, Clinical Pharmacology |
Warfarin (3) | Cardiology or Hematology | PROC | Protein C deficient | Warning and precautions |
No hay comentarios:
Publicar un comentario